Herbert Smith Freehills advises EQT and Icon Group on its acquisition of the Pharmaxo Group

Leading international law firm Herbert Smith Freehills has advised EQT Partners (EQT), a global investment firm and one of the world's largest private equity investors, and its portfolio company Icon Group (Integrated Clinical Oncology Network) on its acquisition of the Pharmaxo Group (the transaction).

Icon is Australia’s largest dedicated cancer care provider and has expanded globally into Singapore, Malaysia, Mainland China, Hong Kong, New Zealand and the UK. The transaction marks a significant milestone in Icon’s on-going growth strategy  ̶  Pharmaxo Group is a leading provider of aseptic compounding services and clinical homecare services.

The transaction is subject to customary regulatory approvals.

The Herbert Smith Freehills team was led by London Corporate Partner and Head of International Private Equity Eleanor Shanks and senior associate Gregor Gordon, assisted by senior associate Nikesh Arya, with associate Aqeel Asif.

The wider deal team included: John Taylor and Raji Azzam (Corporate), Will Nevin and Emma Hallam (Finance) Aurell Taussig and James Tryfonos (Tax); Veronica Roberts and Ali McGregor (Competition, Regulation and Trade); Jeremy Walden, Matthew White, Max Wu, Kalsi Harveen and Shannon McPartland (Real Estate); Susannah Cogman (Disputes), Catherine Howard, Joanne Holbrook and Julie Gouldbourne (Environment, Health and Safety); Miriam Everett, Josie Desmond and Angela Chow (Data Protection);; Andrew Wells, Jessica Welborn, Tim Gollan, and Kate Peck (Intellectual Property); Andrew Taggart, Mark Ife, Lydia Moore and Hannah Gould (Employment, Pension and Incentives); and Frank Thompson (Insurance).

Eleanor Shanks said: "We are delighted to have advised EQT and Icon on this significant and meaningful transaction that will see Icon embark on the next stage of its growth journey, providing critical and innovative healthcare to cancer patients globally. This transaction demonstrates the strength of our private equity offering and expertise in the healthcare and pharmaceutical industries."